BEDMINSTER, N.J.--(BUSINESS WIRE)--Cegedim Dendrite announced today that Bristol-Myers Squibb (NYSE:BMY) has renewed its existing CRM and services contract and will be implementing Mobile Intelligence™, Cegedim Dendrite’s flagship CRM solution, to their Neurosciences sales team. The new agreement also includes the continuance of data and technical support on their current CRM tool. Cegedim Dendrite is the leading provider of Customer Relationship Management (CRM) solutions that increase the efficiency and effectiveness of sales forces in the pharmaceutical industry.
